Galloping rates of SARS-CoV-2 infection in countries including India and Brazil, and inequity caused by advance procurement and nationalism, have imparted an urgency to efforts to increase vaccine access.
While a move initiated by India and South Africa to improve supplies by waiving intellectual property (IP) rights relating to COVID-19 vaccines and therapies has the support of several countries, Nobel Prize winners and even 10 Democratic senators led by Bernie Sanders in the US, global vaccine makers see things differently
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?